Entity > Corporation > AU > Melbourne Victoria > Mesoblast

About Mesoblast

Mesoblast Limited is an Australian-based regenerative medicine company. The company seeks to provide treatments for inflammatory diseases, cardiovascular diseases and back pain

The Phase 3 Product of Mesoblast Limited: The company’s Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Innovative Technology Platform Enables Scalable Manufacturing: Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.

Robust Intellectual Property Estate: Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection in areas of its core commercial focus.

Evidence-based Science and Translational Medicine: Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards composed of independent medical experts and statisticians. These safeguards are intended to ensure the integrity and reproducibility of results, and to ensure that outcomes observed are scientifically reliable.

Founding: Mesoblast was founded in 2004. Its founder and current CEO is Silviu Itescu.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Mesoblast